Fallond Portfolio: PODD out

Insulet Corp (PODD) dipped into the low $22s before it staged its post-morning rally. The drop was enough to hit the stop to close the 500 share position for a -$755 (-6.4%) loss.



Three positions remain in the portfolio as market exposure is reduced following the failed breakouts in large caps and the lagging performance of small caps.

Collective2

Fallond Portfolio: LWAY out

Lifeway Foods (LWAY) was the best play of the summer for the portfolio, but unfortunately the stock undercut what I considered to be support, and the position was stopped out for a reduced profit (an alternative support would be the lows of the big white candlestick i.e. a loss of $17). The 700 share position finished with a +$3,052 (+33.5%) profit. The gains were enough to give a net positive return for August (+2.5% per trade)

Collective2

Fallond portfolio: FOLD, ALLI, and CKSW out

A busy day for the Collective2 portfolio. One play which I forgot to publish last week was the brief 1-day fling for Genomic Health (GHDX). The 500 share lot closed for a -$495 (-4.8%) loss which was a frustrating loss as I looked to increase equity exposure. The three hits for today produced mixed results:

Allion Healthcare (ALLI) did not release any news but the stock jumped 5% on heavier volume in the absence of news. Unfortunately, the stop was hit on the initial break of support. The 1,400 share play closed for a +$252 (+2.8%) profit - but today's exit was a fakeout.



The second stock, ClickSoftware Technologies (CKSW) is set to release earnings on October 31st. But a second day of gains saw the stock tag resistance (and therefore hit its target), for a +27% gain, or a +$2,780 gain on a 2,000 share lot.



Finally, there was a loss for Amicus Therapeutics (FOLD). Although there was no news released on the day, the stock fell back to undercut what looked to be reasonable support. The stock was a morning buy but an afternoon sell. The 500 share position closed for a -$305 (-3.4%) loss.

Five positions remain in the portfolio.

Collective2

Fallond Portfolio: UXG out

The market breakout has turned negative on gold stocks. The stock was entered on the premise of a bounce off the 50-day MA to go test (and break) $7.00 resistance. U.S. Gold (UXG) cut below $6.25 support and its 50-day MA, to run into its stop and close the 1,300 share position for a -$403 loss (-4.92%).



Collective2

Fallond Portfolio: AUXL out

Auxilium Pharmaceuticals (AUXL) undercut $21 support intraday, hitting its stop in the process. The 400 share position closed for a -$592 (-6.7%) loss.

Collective2

Fallond Portfolio: ESMC out

This was a short lived play - entered on the bullish hammer which marked the supposed positive backtest of support, but exited on the break of this support. The hammer should have perhaps been ignored given it didn't occur at an oversold stochastic - I went with price action over the technical read and was caught out. Back to the watch list it goes. The 1,500 share lot closed for a -$600 (-5.82%) loss. Equity exposure is again back to 10% with cash at 90%. After Friday's losses and indices struggles at the 50-day MAs it could be back to the drawing board for this rally (although it is still intact).

Collective2

Fallond Portfolio: UVE and AMSC out

Although I liked recent market lows as a buying opportunity, it has proven hard to stay in a position without allowing for the level of volatility present in the markets. Both of the stocks exited may be worth a second look over the coming weeks, but both are no longer part of the portfolio - leaving it 15% equity and 85% cash, down from 33% equity.

American Superconductor Corp (AMSC) finished with a low volume bullish doji - but intraday lows were enough to exit the 500 share position for a painful -$975 (-9.22%) loss:



Universal Insurance Holdings (UVE) reversed the mini-breakout, bringing the stock back to triangle support. I had ran a tighter stop than the one from my newsletter, closing the 1,400 share position for a -$434 loss (-5.05%):